Many insomnia medications with high specificity have become available recently. They provide a window into the clinical effects of modulating specific brain systems and establish a new guiding principal for conceptualizing insomnia medications: "mechanism matters." A new paradigm for insomnia therapy in which specific drugs are selected to target the specific type of sleep difficulty for each patient includes administering specific treatments for patients with insomnia comorbid with particular psychiatric disorders. This article reviews insomnia medications and discusses the implications for optimizing the treatment of insomnia occurring comorbid with psychiatric conditions.
Keywords: Comorbid psychiatric disorders; Doxepin; Eszopiclone; Insomnia; Personalization; Prazosin; Suvorexant.
Copyright © 2015 Elsevier Inc. All rights reserved.